Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Trial Profile

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Methotrexate (Primary) ; Tocilizumab (Primary)
  • Indications Haemophagocytic lymphohistiocytosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 03 Jan 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
    • 10 Aug 2017 One new drug tocilizumab has been added in the study. Hence purpose, primary endpoint and study design also got updated. Trial focus has been changed from TU to TU and AR. Treatment arms has been changed from one to two.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top